CAXII-IN-3

CAXII-IN-3 is an effective carbonic anhydrase (CA XII) inhibitor with a Ki of 53 nM. CAXII-IN-3 exhibits selective inhibition against multiple human CA subtypes with Kis of 5.3 μM, 75 nM, 1.9 μM, > 10 μM against CA I, CA II, CA IV and CA IX. CAXII-IN-3 mainly inhibits CA II and XII, and reduces aqueous humor production. CAXII-IN-3 exhibits β3-AR agonistic activity, can dilate retinal blood vessels, and improve optic nerve perfusion. CAXII-IN-3 can be used in the research of ocular disorders such as glaucoma[1].

Product Specifications

UNSPSC

12352005

Target

Adrenergic Receptor; Carbonic Anhydrase

Related Pathways

GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling

Field of Research

Neurological Disease

Smiles

NC1=CC=C(C=C1)CCNC[C@@H](C2=CC=CC=C2)OC(NC3=CC(C=C4)=C(C=C3)OC4=O)=S

Molecular Formula

C26H25N3O3S

Molecular Weight

459.56

References & Citations

[1]Ammara A, et al. Repurposing Drug Metabolites into Dual β-Adrenergic Receptor-Carbonic Anhydrase Modulators as Potential Tools for Ocular Disorders. J Med Chem. 2025 Sep 11;68 (17) :18579-18596.